• HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
Tuesday, July 14, 2026
BIOENGINEER.ORG
No Result
View All Result
  • Login
  • HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
        • Lecturer
        • PhD Studentship
        • Postdoc
        • Research Assistant
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
  • HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
        • Lecturer
        • PhD Studentship
        • Postdoc
        • Research Assistant
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
No Result
View All Result
Bioengineer.org
No Result
View All Result
Home NEWS Science News Health

COVID-19 on the brain: Neurological symptoms persist in majority of long-haulers

Bioengineer by Bioengineer
June 15, 2022
in Health
Reading Time: 3 mins read
0
Jennifer Graves, University of California San Diego
Share on FacebookShare on TwitterShare on LinkedinShare on RedditShare on Telegram

Researchers at University of California San Diego School of Medicine are conducting a longitudinal study to track neurological symptoms in COVID-19 “long-haulers.” 

Jennifer Graves, University of California San Diego

Credit: UC San Diego Health Sciences

Researchers at University of California San Diego School of Medicine are conducting a longitudinal study to track neurological symptoms in COVID-19 “long-haulers.” 

The first round of results, published June 15, 2022 in Annals of Clinical and Translational Neurology, revealed the prevalence of various short- and long-term symptoms and found that, while many patients showed improvement, the majority still had some neurological symptoms after six months. A subset of individuals also exhibited significant coordination and cognitive issues, which had not been previously described.

Following mild-to-moderate SARS-CoV-2 infections, 56 persons with neurological symptoms were recruited to the study between October 2020 and October 2021. They completed a neurological exam, cognitive assessment, self-reported questionnaires and an optional brain scan. Baseline measurements were taken a few months after their initial infection and repeated three and six months later.

At the time of their first visit, 89 percent of participants were experiencing fatigue and 80 percent reported headaches. Other common neurological symptoms included memory impairment, insomnia and decreased concentration. Eighty percent of participants said these symptoms impacted their quality of life. 

When participants returned for their six-month follow-up, only one-third reported complete resolution of symptoms. The other two-thirds of participants reported persistent neurological symptoms, though most had diminished in severity. The most prevalent symptoms at six months were memory impairment and decreased concentration. 

The authors noted that none of the individuals with persistent symptoms at six months had any history of pre-existing neurological conditions prior to their SARS-CoV-2 infections.

“It’s encouraging that most people were showing some improvement at six months, but that wasn’t the case for everyone,” said senior author Jennifer S. Graves, MD, PhD, associate professor at UC San Diego School of Medicine and neurologist at UC San Diego Health. “Some of these participants are high-level professionals who we’d expect to score above average on cognitive assessments, but months after having COVID-19, they’re still scoring abnormally.” 

Researchers were also surprised to find a novel phenotype within the cohort. Seven percent of participants displayed a previously unidentified set of symptoms that included cognitive deficits, tremor and difficulty balancing. The authors labeled the phenotype Post-Acute Sequelae of COVID-19 infection with Tremor, Ataxia and Cognitive deficit (PASC-TAC).

“These are folks who had no neurological problems before COVID-19, and now they have an incoordination of their body and possible incoordination of their thoughts,” said Graves. “We didn’t expect to find this, so we want to get the word out in case other physicians see this too.” 

Researchers are still investigating how much the SARS-CoV-2 virus directly invades the brain, but Graves said it is more likely that these delayed neurological symptoms are caused by the infection triggering an inflammatory autoimmune response in the brain. 

The team plans to continue monitoring participants’ symptoms annually for up to 10 years. Additional efforts will evaluate how different COVID-19 variants and vaccines affect long-term neurological symptoms.

“To have people’s cognition and quality of life still impacted so long after infection is something we as a society need to be taking a serious look at,” said Graves. “We still need to know how common this is, what biological processes are causing this, and what ongoing health care these people will need. This work is an important first step to getting there.”

Co-authors include: Jacqueline E. Shanley, Andrew F. Valenciano, Garrett Timmons,  Annalise E. Miner, Visesha Kakarla, Jennifer H. Yang, Amanda Gooding, Marc A. Norman, Sarah J. Banks, NeuCovid Team, Michelle L. Ritter, Ronald J. Ellis and Lucy Horton at UC San Diego, as well as Torge Rempe at University of Florida. 

# # #



Journal

Annals of Clinical and Translational Neurology

DOI

10.1002/acn3.51578

Article Publication Date

15-Jun-2022

COI Statement

Jennifer S. Graves is a steering committee member for an unrelated trial supported by Novartis Pharmaceuticals (grants #26940 and 30805).

Share12Tweet8Share2ShareShareShare2

Related Posts

New Study Links Muscle Health to Diabetes Risk

July 14, 2026

Paintable electrodes advance colorful, flexible wearable sensor technology

July 14, 2026

Half of New York Pedestrian Deaths Linked to Substance-Impaired Awareness

July 14, 2026

Tumor Profiling Reveals Chemotherapy Effects and Personalized Treatments for Ovarian Cancer

July 14, 2026

POPULAR NEWS

  • New Drug Candidate Developed at McMaster Shows Potential for Treating Brain Cancer

    58 shares
    Share 23 Tweet 15
  • Detection of EDCs in Breast Milk and Infant Urine Up to Six Months Highlights Early Exposure Risks

    77 shares
    Share 31 Tweet 19
  • Experimental Therapy Simultaneously Destroys Prostate Tumor Cells and Reactivates Antitumor Immunity

    46 shares
    Share 18 Tweet 12
  • 高齢者の骨粗鬆症治療の持続性比較

    51 shares
    Share 20 Tweet 13

About

We bring you the latest biotechnology news from best research centers and universities around the world. Check our website.

Follow us

Recent News

Nasal Smell Stimulation Reduces Apnea in Premature Infants: Study

New 3D Thermal Cloak Conceals Objects from Heat in All Directions

AI Advances Revolutionize Oncology Drug Discovery from Targets to Therapies

Subscribe to Blog via Email

Enter your email address to subscribe to this blog and receive notifications of new posts by email.

Join 85 other subscribers
  • Contact Us

Bioengineer.org © Copyright 2023 All Rights Reserved.

Welcome Back!

Login to your account below

Forgotten Password?

Retrieve your password

Please enter your username or email address to reset your password.

Log In
No Result
View All Result
  • Homepages
    • Home Page 1
    • Home Page 2
  • News
  • National
  • Business
  • Health
  • Lifestyle
  • Science

Bioengineer.org © Copyright 2023 All Rights Reserved.